Shanghai Bajiayi Pharmaceutical Technology

Shanghai Bajiayi Pharmaceutical Technology Co., Ltd. is a clinical-stage biotechnology company based in China, specializing in the development of innovative therapeutics for cardiovascular and cerebrovascular diseases. The company originated as a translational research platform for discoveries from the Second Military Medical University (Navy Medical University). Its primary pipeline program, BJY-801 (also known as malifopeptide), is a synthetic pentapeptide derived from Monocyte Locomotion Inhibitory Factor (MLIF) and is currently in Phase 1 clinical trials for the treatment of ischemic stroke. Bajiayi's research focuses on the eEF1A1/eNOS pathway for neuroprotection and explores small-molecule STING agonists for potential applications in oncology and inflammatory diseases.